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Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disorder of aging
after Alzheimer's disease (AD). Pathologically, it is characterized by a degeneration of
dopamine (DA) neurons in substantia nigra of middle brain, which causes the motor
symptoms and nonmotor symptoms of PD. The dopamine replacement therapy using
levodopa and surgical treatment of deep brain stimulation (DBS) can only improve the
symptoms of PD, but cannot stop the disease progression. Because of the selective loss of
DA neurons, cell transplantation provides an exciting potential for the treatment of
Parkinson's disease. The available cell sources include mesenchymal stem cells (MSCs)
from bone marrow, neural stem cells (NSCs) from fetal brain tissues, embryonic stem cells
(ESCs) from blastocysts, and induced pluripotent stem cells (iPSCs) reprogrammed from
somatic cells transfected with stem cell transcription factors of OCT4, SOX2, KLF4, and
c‐MYC. Here, we first review the research advance conducted in animal models and
patients of PD with these cells, then moving forward to recent development of iPSCs as
a future source for the treatment of PD, and highlight the current challenges to make good
manufacturing practice (GMP) standard cells suitable for large‐scale production to move
the cell‐based therapy from dish to clinic as soon as possible.
Keywords: cell‐based therapy, dopamine neuron, embryonic stem cell, induced pluri‐
potent stem cell, neural stem cell, Parkinson's disease
1. Introduction
Parkinson's disease (PD) is affecting 1–2% of the population over the age of 60 years old and 3–
5% of the population above the age of 85. Clinically, PD patients are characterized with four
cardinal symptoms of resting tremors, muscle rigidity, bradykinesia, and postural instability.
These motor symptoms appear when 60–80% of dopamine (DA) neurons in the substantia nigra
are degenerated and are used as diagnostic criteria. The nonmotor symptoms have recently
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been  highlighted  as  some  of  these  symptoms  including  depression,  constipation,  pain,
genitourinary problems, and sleep disorders may precede the motor dysfunction and can be
used as early diagnosis and treatment of PD [1].
Because of the decrease of dopamine release in brains of PD patients, either increasing
dopamine levels using drugs such as levodopa or reducing the dopamine degradation by
dopamine inhibitor carbidopa can play therapeutic effects on PD patients [2]. A surgical
treatment called deep brain stimulation (DBS) using electrodes to stimulate to the nucleus
subthalamicus is also effective. However, surgical DBS is only suitable for a small portion of
the patients and has unclear long‐term benefits, while the medications have been found to
decline in effectiveness over time and moreover cause the side‐effect of dyskinesias (involun‐
tary muscle movements). Recently, great treatment potential has been provided through
replacing lost DA neurons using embryonic stem cells (ESCs), induced pluripotent stem
cells (iPSCs) reprogrammed from patients’ somatic fibroblasts or blood cells, neural stem
cells (NSCs), or fully differentiated DA neurons from fetal brain tissue and mesenchymal stem
cells (MSCs) sourced from fetuses or adults [3]. A lot of efforts have been done to find suitable
cells to improve treatments not just of PD, but of all neurodegenerative diseases.
2. Etiology and molecular genetics
The causes of PD can be divided into genetic susceptible genes and environmental toxic
environmental substances such as the pesticide rotenone and manganese, which integrate to
damage the DA neurons through oxidative stress and mitochondrial impairment to induce
PD. The majority of PD cases are sporadic or idiopathic with unknown causes (80–90%); the
remained cases (10–20%) are familial and can be associated with PD‐related genes or linked to
a particular monogenic mutation [4–6]. Genetic factors play a minor role in causing typical PD,
particularly for the patients having PD after 50 years of age [7]. This suggested that genetic
factors are an important factor when the disease begins at or before the age of 50.
Genetic linkage analysis has great power to identify the disease genes for inherited monogen‐
ic diseases. By now more than 200 genes or loci have been characterized for neurological
diseases and more than 100 genes or loci were reported for neuromuscular diseases includ‐
ing PD. The public available database for the genes or loci can be found in online catalog of
human inherited genes and disorders (http://www.ncbi.nlm.nih.gov/omim/). The first gene
for PD is the α‐synuclein gene that was identified in 1997 [8]. Afterward more genes or loci
were found to be responsible for familial PD. The characterized mutated genes for the
autosomal dominant form of PD are SNCA and LRRK2 whereas the early‐onset autosomal
recessive genes for PD are PARK2 (Parkin), PINK1, and PARK7, ATP13A2. Some suscepti‐
ble genes were also reported to be associated with PD such as Tau, Nurr1, and β‐glucocere‐
brosidase (GBA). SNCA, which codes for α‐synuclein, has been particularly well‐studied and
different point mutations (A53T, A30P, and E46K) in SNCA were found in different families
with PD. It seems that the missense mutations of the SNCA gene are rare and the genomic
rearrangements including the duplication and triplications of SNCA are more common to
induce the aggregation of α‐synuclein in the dopamine neurons.
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Leucine‐rich repeat kinase 2 (LRRK2) is another disease gene for autosomal dominant form of
PD. It contains more than 50 exons and codes an 832‐amino acid protein, which plays GTPase
and kinase functions. Mutations can occur in any exons of LRRK2 gene, but the most com‐
mon missense mutations are R1441C, Y1699C, G2019A, and I2020T. The G2019S mutation in
LRRK2 is worldly prevalent, constituting 4% of familial PD cases and 1% of sporadic PD cases.
Identification of mutations in the enzymatic GTPase and kinase domains suggests change of
these enzymatic activities leads to disease development. Studies have shown that R1441 and
Y1699 mutations decrease GTPase activity of LRRK2 whereas G2019S and I2020T mutations
increase kinase activity [9, 10].
The second locus for PD is PARK2 for parkin gene. Parkin mutations were first reported in the
autosomal recessive families of PD. The total genomic size of parkin covered 1.4 Mb. It
contains 12 exons, and the gene product is a protein with 462 amino acids. The parkin has 30%
homology to ubiquitin in the amino terminal domain and has two RING‐finger‐like motifs in
the carboxyl part of the protein. It was reported that the RING‐like structures in parkin have
some ubiquitin‐ligase activity. By now, more than 100 different mutations of parkin were found
in familial and sporadic cases of PD. Most of the Parkin mutations are exonic deletions but
missense, nonsense mutations, and genomic rearrangements were also found in PD families.
In addition to the autosomal dominant or recessive genes, some other genes are also report‐
ed to be associated with PD. NURR1 is one of the important transcription factors to regulate
the development and maturation of the dopamine neurons. We had ever screened 202 familial
and sporadic patients with PD and identified one patient has missense mutation of the NURR1
gene. This mutation produced a truncated NURR1 protein that loses the important function‐
al domain to bind the promoter region of the tyrosine hydroxylase (TH), the key kinase to
control the synthesis of the dopamine neurotransmitter [11]. GBA is another susceptible gene
involved with PD. This gene encodes the lysosomal hydrolase β‐glucocerebrosidase in which
mutations are associated with neurodegenerative diseases, such as PD and GD (Gaucher's
disease). We have performed a case–control study in a Chinese Cohort with PD and a Chinese
control cohort by sequencing all the 12 exons of the GBA gene and found that the PD pa‐
tients have significantly higher frequency of mutations in the GBA gene. Totally, we found
nine reported and three novel GBA mutations in 184 Chinese patients. These known GBA
mutations are R163Q, F213I, E326K, S364S, F347L, V375L, L444P, RecNciI, and Q497R and the
novel mutations are 5‐bp deletion (c.334_338delCAGAA), L264I and L314V. Importantly, we
identified the novel 5‐bp deletion (CAGAA) that produces a nonfunctional GBA protein of 142
amino acids, which loses major enzymatic function domains of the full GBA protein [12].
3. Pathological mechanisms
The mainly pathological mechanism of PD is the degeneration and loss of dopamine (DA)
neurons in the substantia nigra of the mesencephalon. These DA neurons project to the basal
ganglia (the striatum), which is responsible for motor control and function. The loss of DA
neurons is accompanied by Lewy neuritis and Lewy bodies, which cause motor dysfunc‐
tions accompanied by an intensification of the disease, including cognitive impairment which
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encompasses hallucinations, dementia, and speech difficulties. The Lewy neurites might
hamper the survival and dendritic development of neurons and glial cells through forming
insoluble aggregates of α‐synuclein (coded by SCNA), ubiquitin, and other misfolded
proteins [13].
To understand the molecular mechanism and replicate the phenotypic features of PD, different
animal models have been studied to explore dopaminergic neurotoxicity mainly using
transgenic models of the familial PD‐causing genes such as SNCA and LRRK2. The transgen‐
ic mice expressing human SNCA showed pathological inclusions in some neurons and glial
cells, motor behavior deficits, and loss of dopaminergic neuron terminals in the basal ganglia.
Overexpression of SNCA in drosophila leads to age‐dependent dopaminergic neuron
degeneration. Furthermore, the slowness of movement in LRRK2‐G2019S transgenic mouse
models was shown to be associated with diminished dopamine release and axonal patholo‐
gy. These results support a causal role for α‐synuclein in the development of PD. Some studies
also suggest that the cellular toxicity in dopamine neurons may be caused by the soluble
cytoplasmic oligomeric α‐synuclein protein, whereas the large insoluble protein aggregates
may represent a cellular defense mechanism in which the cell eventually convert cytotoxic‐
soluble oligomeric proteins into insoluble inclusion bodies. The α‐synuclein‐containing fibrils
in the degenerative dopamine neurons can disturb cell membrane, leading to increased
membrane permeability and eventual cell death of affected neural cells [14, 15]. Some studies
showed that genetic mutations in PD genes can affect protein trafficking and cellular degra‐
dation machinery and eventually lead to development of PD, but the precise role of these
mutated genes in disease progression and interaction with need to be further explored. A
recent study reported that accumulation of α‐synuclein reduced lysosomal degradation
capacity in human midbrain dopamine neurons. Continuous aggregation of α‐synuclein in the
neural cells disrupted the endoplasmic reticulum–Golgi localization of the key genes such as
RAB1a for vesicular transport. Overexpression of RAB1a restored the protein trafficking in
endoplasmic reticulum–Golgi pathway and reduced pathological accumulation of α‐synu‐
clein in neurons. This study proposes that enhancement of lysosomal trafficking probably play
beneficial roles in synucleinopathies [16]. Another molecular mechanism of PD is lysosomal
dysfunction and the accumulation of glucosylceramide induced by decreased activity of β‐
glucocerebrosidase (GBA). Glucosylceramide played roles in stabilizing toxic oligomeric
forms of α‐synuclein and blocking transport of newly synthesized β‐glucocerebrosidase from
the endoplasmic reticulum to endocytic compartments, increasing the pathological aggrega‐
tion of α‐synuclein in neuronal cells. A recent study revealed that mutation in GBA is a major
risk factor for the development of PD and the molecular pathways of pathological accumula‐
tion of glucosylceramide, related lipids, and α‐synuclein will need to be studied for the
identification of new therapeutic drugs for PD [12, 17].
4. Current stem cell sources for cell‐based therapy of PD
Stem cell sources for the treatment of PD have been studied in the past decades. These cells
mainly include mesenchymal stem cells from bone marrow and placenta; neural stem cells
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(NSCs) and dopamine neurons from fetal brain tissue; embryonic stem cells (ESCs) of the
blastocysts from in vitro fertilization; and induced pluripotent stem cells (iPSCs) reprogram‐
med from autologous somatic cells by expressing transgenes of OCT4, SOX2, c‐MYC, and
KLF4.
4.1. Mesenchymal stem cells
Mesenchymal stem cells (MSCs) were first reported in 1966, and were described as plastic‐
adherent colony‐forming‐unit fibroblastic (CFU‐F) cells. MSCs are multipotent with poten‐
tial to differentiate into different cells of mesodermal lineage and transdifferentiate into
epithelial, endothelial, and neuronal cells. MSCs can be isolated from various neonatal and
adult tissues such as bone marrow, adipose tissue, umbilical cord, cord blood, amnion,
placenta, peripheral blood, and dental pulp [18]. Bone marrow‐derived MSCs (BM‐MSCs) are
a potentially promising source of cells for use in regenerative medicine because they are
abundantly available, easy to isolate from the patient themselves, an autologous tissue, and
there is no ethical dispute over their use. Several studies have shown that BM‐MSCs have the
potential to regenerate DA neurons for the treatment of PD. Human BM‐MSCs also have a
protective effect on the progressive loss of DA neurons induced by carbobenzoxy‐L‐leucyl‐L‐
leucyl‐L‐leucinal (MG‐132) in vitro and in PD rats [19]. After grafted into the striatum, BM‐
MSCs were shown to exert neuroprotective effects against nigrostriatal degeneration and to
improve motor function in 6‐OHDA lesioned rats [20]. BM‐MSCs grown in neuronal differ‐
entiation medium have more pronounced effect and improve the motor defects in a 6‐OHDA
fully lesioned rat PD model. BM‐MSCs were induced to have neural morphology and
expressed markers of DA neurons, such as tyrosine hydroxylase (TH), and most of the cells
survived in striatum, expressed TH and behavioral recovery was observed after the cells were
transplanted to a 6‐OHDA mouse model. A human MSCs‐induced DA subpopulation
combined with pharmacologically active microcarriers grafted in a rat PD model also led to
protection and repair of the nigrostriatal pathway and behavioral recovery.
The role of genetically modified MSCs for the protection and repair of damaged DA neurons
and their therapeutic effects have been studied after implanted into PD models. Park et al.
investigated the potential of MSCs genetically engineered with glial derived neurotrophic
factor (GDNF) by viral transduction to deliver this potent neurotrophic factor for DA neu‐
rons in the brain. They found that MPTP(1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mice
that were intravenously injected with GDNF‐modified BM‐MSCs possessed more TH‐IR
neurons and fibers and showed more prominent behavioral recovery compared with control
mice that were implanted naive BM‐MSCs [21]. Barzilay et al. reprogrammed the BM‐MSCs
toward dopaminergic differentiation through delivery of LMX1a, which was reported to be a
key transcriptional factor of dopaminergic differentiation in both embryonic stem cells and
developmental animal models. They found that the LMX1a protein was concentrated in the
cell nuclei, and the cells with forced expression of LMX1a expressed higher levels of tyrosine
hydroxylase, secreted significantly higher level of dopamine comparison with nontrans‐
duced cells [22]. Wang et al. tested a cytotherapeutic strategy combining cell transplantation
and NTN/Lmx1α gene therapy to ameliorate disease progression in hemiparkinsonian rhesus.
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They found induced rh‐BMSCs exhibited gene/protein expression phenotypes resembling
nigral dopaminergic neurons, and these cells survived and retained dopaminergic function
following stereotaxic injection into the MPTP‐lesioned hemiparkinsonian rhesus [23].
4.2. Neural stem cells and dopamine neurons from fetal brain tissue
Neural stem cells (NSCs) were first described as granule cells with a high proliferative activity
in the brain cortex and middle brains. These cells have self‐renewal and neural differentia‐
tion potential and can differentiate into neurons, astrocytes, and oligodendrocytes. In the
developing brain, the distribution of NSCs demonstrate regionalization. For instance, only
NSCs isolated from the midbrain have been reported to differentiate into A9 mesencephalic
DA neurons necessary for treatment of PD patients. Moreover, NSCs can also be isolated from
the other regions of fetal brain or from the subventricular zone (SVZ) and hippocampus of the
adult mammalian brain, the regions where neurogenesis continues throughout the mamma‐
lian's lifespan [24, 25]. Since initial discoveries of NSCs in 1965, research advances in the
isolation, expansion, and differentiation of NSCs have been made [26]. After transplantation
in the adult rat brain, undifferentiated NSCs show some promise in treatment of PD. Human
NSCs transplanted into the rat brain migrate and differentiate to neurons in a site‐specific
manner. Moreover, in PD rats with depleted host DA levels, engrafted NSCs were sensitive to
environmental factors, appearing to differentiate preferentially to DA neurons.
NSCs can also be modified to overexpress the neurotrophic factors, which can increase the
survival of the transplanted cells. Cai et al. studied some homeodomain proteins selectively
expressed in DA progenitor cells in the ventral midbrain, and found that Lmx1a and Msx1
function as key factors triggering generation of DA neurons. Overexpressing the transcrip‐
tion factor ASCL1 was reported to be able to regain neurogenesis from human neural
progenitor cells and to produce larger neurons with more neurites [27]. Animal study showed
that forcing expression of Nurr1 promoted the mouse NSCs to differentiate into DA neurons
and survive in 6‐OHDA‐lesioned PD rats. After transplantation of rodent and human fetal
brain dopamine neurons to the midbrain of the 6‐OHDA‐lesioned rats, the cells survived well
in the host brains and the motor defects of the PD rats were improved [28, 29]. Based on the
results of animal studies, Lindvall et al. started the first clinical trials by transplanting fetal
dopaminergic neurons or tissue to PD patients. Since then the clinical assessment protocols
have been modified and significant effects were found by detecting behavioral and histolog‐
ical improvement [30, 31]. Moreover, younger PD patients showed more significant improve‐
ments, implying that the treatment efficiency may be limited in certain subpopulations.
Generally, long‐term graft survival was poor and did not convincingly justify the use of three
to five human embryos per procedure [32]. In general, variable functional outcome has been
showed from the clinical trials, but solid improvements need to be determined by clinical and
imaging evaluations in the future [33, 34]. Transplantation of NSCs in PD patients also showed
some side‐effects. Olanow et al. reported that 56% of patients transplanted with fetal mid‐
brain tissue developed persistent dyskinesia after overnight withdrawal of dopaminergic
medication [35], which was much more than Freed et al.'s result of 15% of patients showing
dyskinesias [31]. Its exact prevalence may be argued, while the recurrence of dyskinesia
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following neural transplantation has been well‐proved. Some evidence showed that grafts
containing serotonin neurons were easier to have this detrimental effect, therefore dyskine‐
sias symptom may be alleviated by ensuring a homogeneous cell population in transplanted
tissue [36].
Long‐term follow‐up results were shown in three individual clinical studies. One study found
transplanted fetal midbrain DA neurons survived up to 14 years without pathology [37],
whereas others found that α‐synuclein‐positive Lewy bodies in eventual spread to the
transplanted DA neurons in PD patients [38, 39]. These findings suggest that PD can be an
ongoing process with pathological changes. The controversy may be the reason of the
difference between environmentally and genetically caused PD—a case of PD caused by
environmental factors might be cured by the infusion of healthy cells, whereas a case of PD,
which has been caused by genetic mutations would be an ongoing process. In general, DA
neuron engraftment cannot be stated as a universally permanent treatment for PD; follow‐up
implantations may be further required for optimal effectiveness. Like all other allogeneic
treatments, there is also a risk of graft rejection which must be repressed in the study [40].
Overall, the clinical trials with NSCs of fetal brains showed the survival of the transplanted
cells and some improvements of symptoms in PD patients, whereas some results are over in
dispute because of the diversities or limited cases of the PD patients [34]. Table 1 summarized













1 12 months 1/1 No [41]
6 10–72 months 4/6 No [42]
5 18–24 months 2/5 No [43]
20/40 3 years 17/20 No [31]
23/34 24 months 6/23 Yes [35]
2 8 years 2/2 Yes [44]
5 9–14 years Not available Not available [37]
1 14 years 1/1 Yes [39]
2 11–16 years Not available Not available [38]
33 2–4 years 45% Not available [45]
3 13–16 years Yes Not available [46]
2 18 and 15 years 2/2 Not available [47]
Note: 23/34 indicates that 23 of 34 cases are in the group transplanted with NSCs and the other cases are in the control
group.
Table 1. The clinical trials in PD patients transplanted with fetal brain‐derived neural stem cells.
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To further address the clinical therapeutic effects of the transplanted NSCs, and to provide
new guidelines for clinical trials of fetal brain‐derived cell therapy for PD treatment, a new,
multicenter and collaborative study of European Union (TRANSEURO) was formed in 2010.
These need careful selection of patients: early in the course of their disease (disease duration
2–10 years); aged 30–68 at the time of inclusion, showing a good response to levodopa;
systematically evaluation of cell preparation, and location of transplantation; immunosup‐
pression after transplantation and follow‐up time; numbers of patients and clinical assess‐
ment standards. The new clinical trial for more than 100 patients suffered with PD has
completed in this study, and results are in the analysis [48, 49].
4.3. Human embryonic stem cells (hESCs)‐derived neural stem cells and dopamine neurons
Embryonic stem cells (ESCs) are self‐renewing, pluripotent, and isolated from the inner cell
mass cells of the preimplantation blastocysts. ESC can be differentiated into any kind of tissue
cells including neural stem cells (NSCs), neurons, and DA neurons under special microenvir‐
onment. The differentiated neural stem cells, or fully differentiated neurons and dopamine
neurons from mouse embryonic stem cell have been proved to have effects for PD neuropro‐
tection [50].
Originally, human embryonic stem cells (hESCs) were isolated through culturing inner cell
mass cells using mouse embryonic fibroblasts (MEFs) as feeder cells [51]. Since then, many
groups have developed methods to direct the hESC differentiation to the neural stem cells and
neurons, in particular dopamine neurons for the treatment of PD. Cooper et al. employed sonic
hedgehog (SHH) and FGF8a as patterning factors in DA neuron induction [52]. The differen‐
tiation of hESCs to mesencephalic dopamine neurons was promoted by the application of
specific patterning molecules that regulate mesencephalon development [53] or by applying
growth factors SHH and FGF8a in a specific sequence [54]. Early exposure of FGF8a and SHH
instructs early precursors to adopt a region identity which promotes DA neuron differentia‐
tion from mesencephalic neuroepithelial cells. These hESC‐derived dopamine neurons were
able to improve the motor deficiency of PD rat models, suggesting that grafted hESC‐de‐
rived dopamine neurons played a role in vivo. The efficiency of DA production from pluri‐
potent stem cells was greatly improved by Chamber et al. using a developed protocol through
inhibiting SMAD signaling using Noggin and SB431542, with enhancing survival of mesen‐
cephalic DA neurons from hESCs [55]. They found that addition of Noggin and SB431542 for
inhibiting SMAD signaling is sufficient to induce complete neural conversion of more than
80% of hESCs under adherent culture conditions. Fasano et al. found complimentary results,
showing that neurons in development did not form toward anterior regionalization, but may
be shifted toward a midbrain‐like identity after FGF8 or Wnt1 treatment [56]. The same group
developed a floor‐plate‐based protocol for generating hESCs‐derived DA neurons in differ‐
entiation medium containing activators of sonic hedgehog (SHH) and canonical WNT
signaling in vitro, further improved complete conversion of hESCs to the dopamine neurons
and decreased the teratoma formation in vivo. They found that these DA neurons efficiently
grew for several months in vitro and restored the amphetamine‐induced rotation behaviors
and improvements in tests of akinesia and forelimb use after transplanted to Parkinsonian
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monkeys and 6‐OHDA‐lesioned rats [57]. Sanchez‐Danes et al. reported that using lentiviral
expression of LMX1A, the key DA neuron‐regulating gene, in hESCs to obtain more than 60%
ventral mesencephalic DA neurons of the A9 subtype of all neurons differentiated from
LMX1A‐modified hESC [58]. Grealish et al. studied the functional properties of hESC‐derived
DA neurons in vivo by implanting hESC‐derived mesencephalic dopamine neurons and fetal
brain DA neurons into the brains of PD rats. They found that grafted hESC‐DA neurons
survived, projected long neural branches and played functions to improve the locomotive
deficits of PD rats as similar as fetal brain DA neurons by MRI and PET imaging analysis,
which provided further preclinical basis of hESC‐derived dopamine neurons for PD patients’
treatment [59].
To dissolve the major concerns for clinical use with stromal cells as feeder cells for culturing
hESCs, some groups developed the implementation of factors which substitute for feeder cells.
For example, Schulz et al. used a serum‐free suspension system for generating the neurons,
which are clinically applicable use [60]. Vazin et al. succeeded in substituting growth factors
SDF‐1, PTN, IGF2, and EFNB1 for the PA6 stromal cells, resulting in the induction of differ‐
entiating hESCs directly to TH‐positive DA neurons without requiring this initial induction
step [61]. During differentiating hESCs to NSCs, Swistowski et al. reported that growth factors
SHH and FGF8 substitute for PA6 stromal cells for generating DA cells after an initial induction
step. They endeavored a culture protocol applicable to the clinic and following to the stand‐
ards of good manufacturing protocol (GMP). In their culture process, serum is not involved,
but they found cells could be stored at each of the intermediate stages in their four‐step
process (propagation of ESC→generation of neural stem cells (NSC)→induction of dopami‐
nergic precursors→maturation of dopaminergic neurons) without loss of functional ability,
which is an important discovery that allowing cells to be transplanted at an appropriate time
point in neural development [62].
Though many studies demonstrated hESCs can be differentiated to DA neurons efficiently in
vitro and showed solid functional results to restore the motor defects in PD animal models
including mice, rats, and nonhuman primates, clinical trials have not been performed for
treating the PD patients because of the immune‐rejection and ethical issues.
4.4. Induced pluripotent stem cells (iPSCs)‐derived neural stem cells or dopamine neurons
Previous studies showed an undifferentiated state of cells could be reprogrammed from
differentiated somatic cells using the somatic cell nuclear transfer (SCNT). SCNT technology
is available to make the cloned lambs and cows. However, no studies were described gener‐
ating patient‐specific cells using this SCNT technique [63, 64]. The successful induction of
mouse iPSCs from mouse embryonic and adult fibroblasts were first demonstrated in
Yamanaka lab in 2006 by introducing four transcription factors of Oct3/4, Sox2, c‐Myc, and
Klf4 [65]. Soon afterward, human iPSCs and patient‐specific iPSCs with different diseases
including PD were also generated from several labs by introducing the human orthologs of
these four transcription factors (OCT4, SOX2, c‐MYC, and KLF4) or OCT4, SOX2, NANOG,
and LIN28 [66, 67]. The implication of Oct3/4 and Sox2 was shown to play an essential role in
the propagation of undifferentiated ESCs in culture. The roles of Klf4 and c‐Myc were equally
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undecided. Later studies described that the only genes indispensable in generating iPSCs were
Oct3/4 and Sox2 but not Klf4 and c‐Myc [68]. Similar to ESCs, iPSCs are self‐renew indefinite‐
ly and pluripotent. However, iPSCs overcome the problems associated with BM‐MSCs, fetal
NSCs and hESCs, as they reprogram from the already‐differentiated somatic cells of an
organism back to their embryonic‐like pluripotent state. iPSCs generated from patients will
have wide applications for exploring the molecular mechanisms and cell‐based therapy of
neurodegenerative diseases such as PD [69, 70].
In clinical applications, one of the major advantages of iPSCs over BM‐MSCs, fetal NSCs, and
hESCs is that iPSCs can be generated from the cells of the individual being treated. As the
cultured cells will be autologous, this key trait of iPSCs theoretically enhances their integra‐
tion into the brain tissues of PD patients and minimizes the risk of rejection. Furthermore, the
ethical problems of using aborted fetuses as a cell source are avoided. Once reprogrammed
into iPSC state from the mature cells, the iPSCs can be systematically exposed to specific factors
that promote their differentiation into a specific lineage (such as NSCs or DA neurons) [71].
Until now, a ton of work has been done to improve the generation, differentiation, and
potential clinical applications of iPSCs, especially with great efforts made to bring these
therapeutic cells to meet GMP (good manufacturing practice) standards, to translate them to
the clinic for treatment of neurodegenerative diseases like PD. iPSCs have also been used in
other fields such as diseases model to study the molecular mechanisms of the disease and as
drug screening and discovery.
To determine the clinical potential of iPSCs‐derived cells, the therapeutic effects of mouse
iPSCs were analyzed after transplanting them into the rat brains. Wernig et al. reported that
grafted iPSCs matured into midbrain‐like dopamine neurons, resulting in behavioral im‐
provements in rat PD models [72].
It was found that DA neurons from the iPSCs with LRRK2 mutation (G2019S) were sensitive
to oxidative stress and had α‐synuclein aggregation and more expression of key oxidative
stress‐response genes. The phenotypic neurodegeneration of the differentiated DA neurons
could be rescued by correction of LRRK2 G2019S mutation in iPSCs, supporting LRRK2
mutation playing an important role in the pathogenesis of PD [73]. The virus‐free PD‐iPS cells‐
derived DA neurons were transplanted to the 6‐OHDA‐lesioned rats and it was found that
these DA neurons survived and provided functional improvements in PD rats by alleviating
motor defects induced by apomorphine [74]. Recently, our lab made efforts to generate of iPS
cells by retrovirus‐mediated expression of OCT4, SOX2, c‐MYC, and KLF4 from skin fibro‐
blasts of PD patients and control individuals, and studied the differentiation of iPSCs to NSCs
and DA neurons, and then transplanted the iPSCs‐derived NSCs into the striatums of the 6‐
OHDA‐induced PD rats. iPSCs carrying the transgenes can also be differentiated to the NSCs
and be fully differentiated to neurons and DA neurons in vitro and in vivo. The grafted iPS
cells‐derived NSCs significantly improved the rotational asymmetry of PD rats [4]. Further
work are needed to improve the differentiation efficiency of neurons and DA neurons by
incorporating growth factors and iPSCs together for transplantation, or elevating the dose of
immune‐suppressive agents to lower the immune‐rejection against the human‐derived cells,
or renewing the cell culture protocols.
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Much work has been done toward improving the efficiency of iPSCs generation in absence of
c‐Myc. Stadtfeld et al. reprogrammed mouse liver cells into iPSCs using nonintegrating,
replication‐incompetent adenoviruses carrying the classic four transcription factors [75]. Okita
et al. developed an approach that repeated transfection of plasmids containing the appropri‐
ate genes (one containing the complementary DNAs of Oct3/4, SOx2, and Klf4; the other, c‐
Myc) into embryonic fibroblasts could generate iPSCs [76]. Yu et al. developed a further
protocol to iPSC generation by using nonintegrating episomal vectors, which allows the
derivation of iPSCs free of vector and transgene sequences completely [77]. The direct protein
transduction system free of DNA vector was also proposed to generate iPSCs to remove
potential risks in association with chromosomal integrations and mutations [78].
This claim is verified by the follow‐up study through comparing the cellular properties of
human iPSCs (hiPSC) generated by chromosome integrating with nonintegrating methods.
They found consistent differences in cellular and differentiation properties between hiPSCs
from nonintegrating and integrating reprogramming factors. According to their results,
protein‐based reprogramming of cells into hiPSCs resulted in cells showed no obvious
exogenous reprogramming gene expression, therefore behaved most similar to hESCs [79].
Many efforts have been done to achieve clinical‐grade DA neurons with a stable phenotype,
the A9 subtype DA neurons. From both human ES/iPS cells, a strategy for efficient differen‐
tiation and sorting DA neurons has been developed by Isacson et al. From iPSC‐differentiat‐
ed neural cells, the NCAM (+)/CD29 (low)‐enriched ventral mesencephalic DA neurons were
sorted. The sorted neurons were positive for EN1/TH and FOXA2/TH and had elevated
expression levels of GIRK2, FOXA2, PITX3, LMX1A, NURR1, TH, and EN1 which indicated
that the sorted neural cells are DA neurons. These iPSC‐derived DA neurons were able to
restore behavior activity of PD rats after transplantation. The sorted cells transplanted to the
PD rats were integrated into the brain tissue. Their results provided molecular basis for the
safety and feasibility of iPSC‐derived cell therapies [80].
The similarity and differences between iPSCs and ESC is another issue about iPSCs. Many
studies succeeded in generating both human iPSCs and mouse iPSCs identical to ESCs
developmentally and epigenetically by improving end points for the reprogramming
process [81]. Other groups have also made modifications to reduce the mutagenic potential of
the lentiviruses and retroviruses By using non-integrating methods or omitting the KLF4 or c-
MYC. For instance, Muller et al. found that substituting Nanog and Lin28 for Klf4 and c‐
Myc [67] was one way to reduce this risk. The reactivation of the c‐Myc retrovirus particularly
promotes the risk of mutations, because of tumorigenicity [82]. However, the efficiency of iPSC
formation was far lower after eliminations of c‐Myc from the protocol. This suggests that the
role of c‐Myc is not being necessary in the establishing pluripotency itself but to accelerate
proliferation or otherwise enhance the speed of events establishing pluripotency [83].
Although the generated iPSCs in morphology, growth properties, and differentiation into
different germ layers were very similar to ESCs, differences between iPSCs and ESCs were
detected, which may be the reason by using different iPSC lines [84]. Recently at the molecu‐
lar levels, the similarity and difference between iPSCs and hESCs were studied. In one study,
Koyanagi‐Aoi et al found that only two hiPSC lines had different gene expression and DNA
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methylation through analyzing 49 hiPSC lines and 10 hESC lines. And they found that only
seven hiPSC lines formed some undifferentiated cells by comparing neural differentiation in
vitro between 40 hiPSC lines and 10 hESC lines. This study showed that hiPSCs are very similar
to hESCs [85].
The important point is that such protocols need to meet a xeno‐free, scalable system for the
clinic. A suspension culture system was created for the neural differentiation of hESCs and
hiPSCs [86]. Such systems allowed long‐term cell culture while keeping appropriate marker
expression, normal karyotype, and pluripotency. To decrease the effects of transgenes on iPSCs
functions, several labs developed protocols to use two or three factors to generate iPSCs. Using
single factor of OCT4 in combination of small molecules of VPA, TGF‐β inhibitor (616452),
CHIR 99021, iPSCs can be reprogrammed from mouse adult and embryonic fibroblasts [68].
Omitting the OCT4, the naive iPSCs derived from rhesus monkey fibroblasts can be ob‐
tained with only small molecules, which provided a valuable cell source for further use in
disease modeling and preclinical study [87]. Though iPSCs bring great potentials to the cell‐
based PD therapy, much work is needed for the researchers to find other convenient method
to obtain DA neurons as the complicated procedures for generation, characterization, and
differentiation to the DA neurons. Directly reprograming the fibroblasts of PD patients to DA
neurons is one of the other approaches. Using different combinations of transcription factors
such as Nurr1 (Nr4a2), Mash1 (Ascl1), Sox2, Ngn2, Lmx1a, and Pitx3, DA neurons were
directly reprogrammed from the fibroblasts [88, 89]. Since the lentiviral vectors were used to
express the genes related in most direct reprogramming methods for development of DA
neurons, this can cause the safety concerns for use of the directly reprogrammed DA neu‐
rons in PD patients. However, the research advance will overcome these issues and finally
bring these cells to clinical trials for PD.
5. Future aspects and challenges for clinical application of iPSCs
The NSCs and DA neurons from fetal brain and hESCs are not suitable for wide clinical use
because of their immune‐rejections and ethical issues. The availability of iPSCs has great
potential for autologous cell‐based therapy of PD. The treatment of eye‐disorders using iPSCs
for clinical trial has been initiated in Japan. However, several aspects of iPSCs are further
needed to be resolved for clinical use. These include genetic and epigenetic abnormalities, low
yields of DA neurons, and the safety of iPSC‐derived cells.
5.1. Low yield
Low yield of fully reprogrammed cells is by no means an inherent property of iPSC genera‐
tion and there will continue to be yield improvements in the future. Low yield is a potential
problem, addition of VPA and other chemicals increased the original yields of 0.05% [90]. iPSCs
can theoretically be sourced from anywhere on the adult human, such as stomach cells, liver
cells, and human hair cells, with varying yields across experiments [75]. In fact, Aasen et al.
generated keratinocyte‐derived iPSCs using cells from adult human hairs with a 100‐fold
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increase in efficiency compared to human fibroblast reprogramming, and found these iPSCs
were indistinguishable from ESCs [91]. In any case, with the goal of optimizing methods for
maximum cell yield of iPS cells, avenues must include comparisons between method efficien‐
cies in the future.
5.2. Genetic and epigenetic abnormalities
It is unclear whether iPSCs cells toward a cell fate related to their donor source or otherwise
maintaining a reprogramming signature after differentiation [92]. For the generation of clinical
applicable iPS cells, the lentivirus or retrovirus‐mediated reprogramming methods should be
replaced by nonintegrating vectors to express the reprogramming genes or combine with small
molecules [93]. Some iPSCs from PD patients may also have gene mutations such as chromo‐
somal structure variation, point mutation, gene deletions, and duplications [12, 94]. It is not
suitable to use the cells derived from iPSCs with genetic mutations for direct transplantation
as the functions of cells are affected by the genetic mutations. Many reports developed
protocols to correct the mutation in PD patient‐derived iPSCs. Reinhardt et al. showed that
iPSCs with LRRK2 G2019S mutation was corrected and the LRRK2 correction produced
phenotype rescue in differentiated neurons [73]. Soldner et al. reported that the iPSCs with
SNCA mutation (A53T) was repaired using zinc‐finger nuclease (ZFN)‐mediated nuclease
approach and genetic repair of the A53T mutation in the patient‐derived iPSCs did not affect
the differentiation ability to dopaminergic neurons. The correctly repaired patient‐derived
iPSC lines were confirmed through PCR genotyping and sequencing analysis [95].
5.3. Safety and purity
It is required that the residues of undifferentiated iPSCs should be less than 1% to avoid the
teratoma formation after transplantation, in the aim to obtain iPSC‐derived NSCs or DA
neurons for transplantation. FACS or other noninvasive magnetic selections were used for
developing the approaches to sort the iPSC‐derived cells. Moreover, the cell culture in feeder‐
free conditions are needed to avoid the contamination of animal sources. Currently, murine‐
derived feeder cells are widely used to maintain hESCs and hiPSCs. In addition, these feeder
cells are normally cultured in culture medium including fetal bovine serum (FBS). This would
enhance the possibility to cause the allogenic cell contamination of the iPSC‐derived cells.
Nakagawa et al. developed a new feeder‐free system to culture the hESCs and iPSCs in
StemFit™ medium, which made a big step to make clinically applicable GMP‐standard cells
[96].
6. Conclusion: moving forward to the clinic
Cell‐based therapy holds clinical potential for the treatment of many neurodegenerative
disorders including PD. The use of BM‐MSCs, fetal NSCs, and ESCs is facing with safety and
ethical concerns. However, recently great advance is making in developing iPSC‐derived cells
for PD. Animal studies using injection iPSCs and their derivatives into animal models have
Stem Cell Therapy for Parkinson's Disease
http://dx.doi.org/10.5772/63340
305
shown promise in treatment of disorders such as PD. However in clinical trials for PD, iPSCs
have not been used until their limitations are overcome. Therefore, a relevant therapeutic
progenitor or mature cell type may be identified and grafted in such treatments; in the case of
PD, the options are of course iPSC‐derived DA neurons and iPSC‐derived NSCs.
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